Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?

生物相容性是否会导致输血相关的不良反应?

基本信息

  • 批准号:
    10080105
  • 负责人:
  • 金额:
    $ 67.74万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-01-15 至 2022-12-31
  • 项目状态:
    已结题

项目摘要

Project Summary Nearly 15 million transfusions are performed in the United States each year, with approximately 425,000 units transfused to pediatric patients alone. Despite the frequency – transfusion procedures are not without risk. Blood transfusion complications may be attributed to heavy exposure to plastic devices, which are fabricated with chemicals that exert endocrine disrupting properties. The proposal's main hypothesis is that plastic devices are not universally biocompatible – and that local and systemic reactions to chemical contaminants contribute to transfusion-related complications. The proposal's objective is to assess whether medical device biocompatibility and chemical exposures are underlying contributors to cardiovascular and autonomic dysfunction. The proposal also aims to identify safer biomaterials, chemicals and/or surface coatings for transfusion devices and blood banking. In this proposal, we will build upon our preliminary studies to address three specific aims: 1) To define the extent to which biomaterial leaching and chemical exposure alters cardiovascular and autonomic function, using in vivo and whole heart models. 2) To determine if biocompatibility and incidental chemical exposures are correlated with cardiovascular and autonomic abnormalities in transfused pediatric patients. 3) To compare and contrast alternative biomaterials, chemicals and fabrication techniques in order to identify safer replacements for transfusion-related devices. The proposed application will quantify the role of biocompatibility and chemical leaching on cardiovascular and autonomic function – two targets that are highly susceptible to xenobiotic toxicity. If adverse outcomes are observed in the proposed study, it will pinpoint additional variables to monitor in future clinical investigations and epidemiological studies. Finally, this proposal aims to provide the foundation for objective decision making regarding the use of chemical additives with endocrine disrupting properties in medical device manufacturing by scientific, medical and regulatory communities. Results of the proposed studies can incentivize and accelerate the development and clinical adoption of alternative biomaterials, additives and/or fabrication techniques to improve transfusion patient safety.
项目摘要 美国每年进行近1500万例输血,约42.5万例 仅为儿科病人输血。尽管输血频率很高,但输血程序并非没有风险。血样 输血并发症可能归因于大量接触塑料设备,这些塑料设备是用 具有扰乱内分泌功能的化学物质。该提案的主要假设是塑料设备是 不是普遍的生物相容--局部和系统对化学污染物的反应有助于 与输血相关的并发症。该提案的目的是评估医疗器械的生物兼容性 化学物质暴露是心血管和自主神经功能障碍的潜在贡献者。这项建议 还旨在确定用于输血设备和血液的更安全的生物材料、化学品和/或表面涂层 银行业。在这项建议中,我们将以我们的初步研究为基础,解决三个具体目标:1)界定 生物材料浸出和化学物质暴露改变心血管和自主神经功能的程度, 采用活体模型和全心模型。2)确定生物兼容性和附带的化学暴露是否 与输血儿童患者的心血管和自主神经异常相关。3)比较和 对比替代生物材料、化学品和制造技术,以确定更安全的替代品 与输血相关的设备。拟议中的应用将量化生物兼容性和化学物质的作用 对心血管和自主神经功能的淋洗--这两个目标非常容易受到异物毒性的影响。 如果在拟议的研究中观察到不利的结果,它将确定未来需要监测的其他变量 临床调查和流行病学研究。最后,这项提案旨在为 关于在医疗中使用具有内分泌干扰特性的化学添加剂的客观决策 科学、医疗和监管机构制造设备。建议的研究结果可以 鼓励和加速开发和临床采用替代生物材料、添加剂和/或 提高输血患者安全性的制造技术。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Nikki Gillum Posnack其他文献

Nikki Gillum Posnack的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Nikki Gillum Posnack', 18)}}的其他基金

Off-label drugs in cardiology: evaluating age- and disease-appropriate therapies
心脏病学中的标签外药物:评估适合年龄和疾病的疗法
  • 批准号:
    10578746
  • 财政年份:
    2022
  • 资助金额:
    $ 67.74万
  • 项目类别:
Does Biocompatibility Contribute to Transfusion-Related Adverse Effects?
生物相容性是否会导致输血相关的不良反应?
  • 批准号:
    10321632
  • 财政年份:
    2018
  • 资助金额:
    $ 67.74万
  • 项目类别:
The effect of endocrine disrupting chemicals on cardiac physiology
内分泌干​​扰化学物质对心脏生理的影响
  • 批准号:
    8618646
  • 财政年份:
    2014
  • 资助金额:
    $ 67.74万
  • 项目类别:
The effect of phthalates on the heart: molecular pathways and clinical relevance
邻苯二甲酸盐对心脏的影响:分子途径和临床相关性
  • 批准号:
    8003464
  • 财政年份:
    2011
  • 资助金额:
    $ 67.74万
  • 项目类别:
The effect of phthalates on the heart: molecular pathways and clinical relevance
邻苯二甲酸盐对心脏的影响:分子途径和临床相关性
  • 批准号:
    8207323
  • 财政年份:
    2011
  • 资助金额:
    $ 67.74万
  • 项目类别:
The effect of phthalates on the heart: molecular pathways and clinical relevance
邻苯二甲酸盐对心脏的影响:分子途径和临床相关性
  • 批准号:
    8402828
  • 财政年份:
    2011
  • 资助金额:
    $ 67.74万
  • 项目类别:

相似海外基金

Investigating the Adoption, Actual Usage, and Outcomes of Enterprise Collaboration Systems in Remote Work Settings.
调查远程工作环境中企业协作系统的采用、实际使用和结果。
  • 批准号:
    24K16436
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
WELL-CALF: optimising accuracy for commercial adoption
WELL-CALF:优化商业采用的准确性
  • 批准号:
    10093543
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Collaborative R&D
Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    EU-Funded
Assessing the Coordination of Electric Vehicle Adoption on Urban Energy Transition: A Geospatial Machine Learning Framework
评估电动汽车采用对城市能源转型的协调:地理空间机器学习框架
  • 批准号:
    24K20973
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 67.74万
  • 项目类别:
    EU-Funded
De-Adoption Beta-Blockers in patients with stable ischemic heart disease without REduced LV ejection fraction, ongoing Ischemia, or Arrhythmias: a randomized Trial with blinded Endpoints (ABbreviate)
在没有左心室射血分数降低、持续性缺血或心律失常的稳定型缺血性心脏病患者中停用β受体阻滞剂:一项盲法终点随机试验(ABbreviate)
  • 批准号:
    481560
  • 财政年份:
    2023
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Operating Grants
Our focus for this project is accelerating the development and adoption of resource efficient solutions like fashion rental through technological advancement, addressing longer in use and reuse
我们该项目的重点是通过技术进步加快时装租赁等资源高效解决方案的开发和采用,解决更长的使用和重复使用问题
  • 批准号:
    10075502
  • 财政年份:
    2023
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Grant for R&D
Engage2innovate – Enhancing security solution design, adoption and impact through effective engagement and social innovation (E2i)
Engage2innovate — 通过有效参与和社会创新增强安全解决方案的设计、采用和影响 (E2i)
  • 批准号:
    10089082
  • 财政年份:
    2023
  • 资助金额:
    $ 67.74万
  • 项目类别:
    EU-Funded
Collaborative Research: SCIPE: CyberInfrastructure Professionals InnoVating and brOadening the adoption of advanced Technologies (CI PIVOT)
合作研究:SCIPE:网络基础设施专业人员创新和扩大先进技术的采用 (CI PIVOT)
  • 批准号:
    2321091
  • 财政年份:
    2023
  • 资助金额:
    $ 67.74万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了